opicapone   Click here for help

GtoPdb Ligand ID: 8988

Synonyms: BIA 9-1067 | compound 37d [PMID: 20334432] [2] | Ongentys® | Ontilyv®
Approved drug
opicapone is an approved drug (EMA & UK (2016), FDA 2020)
Compound class: Synthetic organic
Comment: Opicapone is a novel third generation, long-acting catechol-O-methyltransferase (COMT) inhibitor [2]. This mechanism reduces peripheral degradation of levodopa as used as Parkinson's disease therapy.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 123.17
Molecular weight 412
XLogP 3.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC1=CC(=c2o[nH]c(n2)c2c(C)c(Cl)c([n+](c2Cl)[O-])C)C=C(C1=O)[N+](=O)[O-]
Isomeric SMILES OC1=C/C(=c/2\o[nH]c(n2)c2c(C)c(Cl)c([n+](c2Cl)[O-])C)/C=C(C1=O)[N+](=O)[O-]
InChI InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22H,1-2H3,(H,18,19)/b15-7-
InChI Key HVGGGVAREUUJQV-CHHVJCJISA-N
No information available.
Summary of Clinical Use Click here for help
Ferreira et al. (2015) published results from Phase 3 trial NCT01568073 [1]. EMA marketing authorisation was approved in 2016, as an adjunct to a levodopa/cardiodopa regimen to reduce 'off' episodes in Parkinson's disease patients. FDA approval followed in 2020.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
COMT is an enzyme that degrades catecholamines, including levodopa (dopamine precursor) used to treat Parkinson's disease (PD). By inhibiting COMT action, opicapone is expected to prolong the bioavailability of levodopa in combination PD therapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01568073 Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Phase 3 Interventional Bial - Portela C S.A.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)